• Vernakalant Hydrochloride: AF Assay Workflows

  2026-09-07

  Vernakalant Hydrochloride supports translational studies that connect atrial ion-channel pharmacology with rapid conversion of atrial fibrillation. This guide presents exposure-aware cell assays, PK-linked interpretation, workflow controls, and troubleshooting strategies for RSD1235 research.

• Ridaforolimus for mTOR Cancer Research

  2026-09-07

  Ridaforolimus, also called Deforolimus or MK-8669, gives researchers a nanomolar tool for connecting mTOR pathway inhibition with proliferation, protein synthesis, VEGF output, and treatment response. This guide translates its reported activity into practical cancer-cell workflows while showing how machine-learning-derived senolytic research can inform assay design without overstating the evidence.

• Pexidartinib: From Microglia to Tumor Macrophages

  2026-09-05

  Pexidartinib (PLX3397) offers translational researchers a selective chemical entry point into CSF1R biology, connecting macrophage control in oncology with broader principles of myeloid regulation. This article interprets recent evidence on microglial activation and seizure susceptibility to define a disciplined strategy for tumor microenvironment studies, including experimental validation, competitive positioning, and translational limits.

• Wnt agonist 1: Practical Pathway Activation

  2026-09-04

  Wnt agonist 1, also known as BML-284, provides a controllable small-molecule entry point for β-catenin/TCF signaling studies. This guide connects dose-response design, differentiation and developmental assays, and a hypothesis-driven cancer workflow to practical handling and troubleshooting decisions.

• Rotenone: A Mechanistic Guide to Mitochondrial Stress

  2026-09-04

  Rotenone is a mitochondrial Complex I inhibitor used to model respiratory failure, oxidative stress, apoptosis, and neurodegeneration. This guide extends beyond routine protocols by connecting mitochondrial assay design with the compartment-specific immunometabolic insights reported in recent macrophage research.

• EPI-001 and the Next Frontier of AR-Driven Oncology

  2026-09-03

  EPI-001 offers a mechanistically differentiated way to study androgen receptor signaling by targeting the receptor’s N-terminal domain. This article connects prostate cancer and TNBC evidence, outlines translational workflows, and explains how AR/ARv7 biology may guide future research decisions.

• Candida EVs Repress Hyphae Through NRG1

  2026-09-03

  This study identifies a concentration- and time-dependent self-regulatory role for Candida albicans extracellular vesicles (EVs): accumulated EVs suppress hyphal development by activating the SKO1–NRG1 transcriptional axis and reducing hyphal gene expression. The same pathway was associated with improved survival and lower organ fungal burden in a mouse candidemia model, although the responsible EV cargo proteins and clinical relevance require further definition.

• Ridaforolimus: mTOR Workflow for Cancer Research

  2026-09-02

  Ridaforolimus, also called Deforolimus or MK-8669, gives researchers a target-proximal way to connect mTOR signaling with proliferation, VEGF output, and stress phenotypes. This workflow combines dose-response profiling, phosphoprotein validation, apoptosis assay design, and senescence-aware controls without incorrectly labeling mTOR inhibition as senolysis.

• THZ1 and the Transcription Quality-Control Gate

  2026-09-02

  THZ1 is a covalent CDK7 inhibitor that connects transcriptional control with cancer-cell vulnerability. This article interprets THZ1 through new RNA polymerase II quality-control findings, helping researchers design more discriminating transcription and apoptosis assays.

• Biotin-16-UTP for Reliable RNA Mechanism Studies

  2026-09-01

  Learn how Biotin-16-UTP, SKU B8154, supports reproducible in vitro RNA labeling when proliferation, viability, or cytotoxicity results require mechanistic follow-up. This scenario-based guide covers compatibility, optimization, interpretation, and practical product-selection criteria.

• GW 4869 for Exosome–Kidney Research

  2026-09-01

  GW 4869 provides a practical way to test whether neutral sphingomyelinase-dependent vesicle release contributes to podocyte–endothelial injury. This workflow translates lupus nephritis findings into controlled donor–recipient assays while emphasizing vehicle, viability, particle, and cargo controls.

• LY294002: PI3K Signaling in Mechanistic Assays

  2026-08-31

  LY294002 is a reversible class I PI3K inhibitor for dissecting Akt/mTOR-dependent phenotypes. This article connects its pharmacology with microglial amyloid-β uptake assays, emphasizing causal controls, pathway timing, and limits of interpretation.

• Sumatriptan Succinate: Research Workflows

  2026-08-31

  Build receptor-informed migraine, neuroinflammation, and metabolism assays with Sumatriptan Succinate, a practical 5-HT1 receptor agonist for translational research. This guide connects concentration selection, CGRP and cytokine readouts, formulation control, and troubleshooting in one experimentally actionable workflow.

• LY2109761 Workflow for TGF-β Signaling Studies

  2026-08-30

  LY2109761 enables controlled interrogation of TGF-β receptor signaling in cancer, fibrosis, and epithelial plasticity models. This workflow connects receptor-level inhibition with Smad2/3 readouts, Sca-1 phenotyping, radiosensitivity assays, and practical troubleshooting.

• Ro 3306: Temporal Control of CDK1 and DNA Repair

  2026-08-29

  Ro 3306 is a selective CDK1 inhibitor for resolving how mitotic timing shapes cell-cycle arrest, DNA repair, and cancer cell synchronization. This guide connects quantitative CDK1 pharmacology with new TopBP1 inhibitor findings to improve assay design and interpretation.

7972 records 4/532 page Previous Next 12345 下5页 Last page